News Pfizer finally decides not to split up company Company will remain as one, but Read keeps his options open
News Pfizer's breast cancer drug step closer to EU approval Ibrance is already Pfizer's top oncology product.
Views & Analysis Digital Health Round-up – Verily's diabetes ambitions; IBM W... A round-up of this week’s top digital healthcare news. Marco Ricci reports.
Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
News Pfizer to buy AstraZeneca antibiotics for up to $1.5bn AZ continues to sell off already marketed drugs.
News NHS to fund Pfizer's Bosulif and Lilly's Alimta NICE is reviewing drugs from old Cancer Drugs Fund.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.